Case File
efta-efta01107161DOJ Data Set 9OtherBioReference
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01107161
Pages
5
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
BioReference
PRELIMINARY
LABORATORIES
D
0
T
C
R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720)
P: (212)879-0800
S1
L
Notes: NON FASTING
EPSTEIN, JEFFREY
P DOB:
Age: 63 y Sex: M
A U/FL:
Bed:
T Rm:
I Patient ID:
E Address:9 EAST 71ST STREET,
N
NEW YORK, NY 10021
P: (212)772-9416
1
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time
CLINICAL REPORT
[
Clinical Abnormalities Summary:
Triglycerides
INTR.NORM.RATIO(INR)
PROLACTIN, SERUM
Hemoglobin A1C
(May not contain all abnormal results; narrative results may not have
abnormal flags. Please review entire report.)
HDL CHOL., DIRECT
24 LO
6.0 HI
.
Test
Result
Abnormal
erence
•rev ous •esu
Total Protein
6.7
5.9-8.4
g/dL
7.1
10/27/2015
Albumin
4.2
3.5-5.2
g/dL
4.6
10/27/2015
Globulin
2.5
1.7-3.7
g/dL
2.5
10/27/2015
AA Ratio
1.7
1.1-2.9
1.8
10/27/2015
Glucose
99
70-99
mg/dL
95
10/27/2015
Sodium
141
135-147
mmol/L
135
10/27/2015
NOTE: New reference range for Sodium effective 11/16/15.
Potassium
4.2
3.5-5.5
mmol/L
4.2
10/27/2015
NOTE: New reference range for Potassium effective 11/16/15.
Chloride
102
96-108
mmol/L
96
10/27/2015
C02
26
22-29
mmol/L
26
10 27 2015
BUN
22
8-23
mg/dL
21
10/27/2015
Creatinine
1.11
0.80-1.30
mg/dL
1.03
10/27/2015
e-GFR
70
>or•60
mL/min
77
10/27/2015
e-GFR, African American
81
>or=60
mL/min
89
10/27/2015
BUN/Creat Ratio
19.8
10.0-28.0
20.4
10/27/2015
Calcium
9.8
8.6-10.4
mg/dL
9.7
10/27/2015
Uric Acid
7.5
3.4-8.5
mg/dL
6.2
10/27/2015
Iron
75
45-160
ug/dL
57
10/27/2015
Bilirubin, Total
0.5
<1.2
mg/dL
0.5
10/27/2015
LD
171
135-225
U/L
177
10/27/2015
Alk Phos
43
40-156
U/L
62
10/27/2015
AST
29
<40
U/L
23
10/27/2015
PHOSPHORUS
3.4
2.7-4.5
mg/dL
3.3
10/27/2015
ALT
29
<41
U/L
25
10 27 2015
GGTP
18
10-71
U/L
15
10/27/2015
-* C•'rl 0V•SCUL•'/LI•I0S *--
Cholesterol
143
<200
mg/dL
210 HI
10/27/2015
BioReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, NJ 07407 I (800) 229-5227
James Weisberger M.D.
Page 1 of
S
LaboratorylNrector
Printed 01/28/2016 15:30
459 HI
0.97 LO
3.0 LO
EFTA01107161
BioReference
D
LnBORATO
RTES
T
C
R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720)
P: (212)879-0800
51 li
-
EPSTEIN, JEFFREY
P DOB:
Age: 63 y Sex: M
A U/FL:
Bed:
I Rm:
I Patient ID:
E Address:9 EAST 71ST STREET,
N
NEW YORK, NY 10021
I
p: (212)772-9416
PRELIMINARY
1
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time
CLINICAL REPORT
Test
Result
Abnormal
Reference
Units
Previous Result Date
Triglycerides
459 HI
<150
mg/dL
348 HI
10/27/2015
HDL CHOL., DIRECT
24 LO
>40
mg/dL
29 LO
10/27/2015
HDL as % of Cholesterol
17
>14
%
14 *
10/27/2015
Evaluation: AVERAGE RISK
Chol/HDL Ratio
6.0
<7.4
I
7.2
10/27/2015
Evaluation: AVERAGE RISK
LDL/HDL Ratio
Can't Calc
<3.56
3.83 MI
10/27/2015
LDL Cholesterol
Can't Calc
<100
mg/dL
111 HI
10/27/2015
NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL.
VLDL, CALCULATED
Can't Calc
7-32
mg/dL
I
70 HI
110/27/2015
Can't Calc: One or more components was outside the measurable
range. We are unable to calculate.
* HEMATOLOGY *
WBC
7.12
3.40-11.80
x10(3)/uL
6.33
10/27/2015
RBC
4.96
4.20-5.90
x10(6)/uL
5.01
10/27/2015
HGB
14.3
12.3-17.0
gm/dL
14.6
10/27/2015
HCT
41.3
39.3-52.5
41.9
10 27 2015
MCV
83.3
80.0-100.0
fL
83.6
10/27/2015
MCH
28.8
25.0-34.1
pg
29.1
10/27/2015
MCHC
34.6
29.0-35.0
gm/dL
34.8
10/27/2015
RDW
13.9
10.9-16.9
%
14.4
10/27/2015
POLYS
49.2
36.0-78.0
%
51.1
10/27/2015
LYMPHS
36.2
12.0-48.0
%
37.1
10/27/2015
MONOS
7.6
0.0-13.0
5.8
10/27/2015
EOS
6.5
0.0-8.0
%
5.4
10/27/2015
BASOS
0.4
0.0-2.0
%
0.6
10/27/2015
IMMATURE GRANULOCYTES
0.1
0.0-1.6
%
0.0
10/27/2015
Platelet Count
222
144-400
x10(3)/uL
257
10/27/2015
MPV
9.5
8.2-11.9
fL
9.0
10/27/2015
PT
10.1
9.1-11.9
sec
10.0 LO
10/27/2015
NOTE: New reference range for Protime effective 11/10/15.
INTR.NORM.RATIO(INR)
0.97 LO
2.00-3.00
I
0.92 LO
10/27/2015
CLINICAL INDICATIONS FOR INR USE
BioReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, N) 07407 I (800) 229-5227
James Weisberger M.D.
Page 2 of
5
Laboratory Director
Printed 01/28/2016 15:30
EFTA01107162
BioReference
PRELIMINARY
LABORATORIES
D
0
T
C
R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720)
P: (212)879-0800
S1
EPSTEIN, JEFFREY
P DOB:
Age: 63 v Sex: M
A U/FL:
Bed:
T Rm:
I Patient ID:
E Address:9 EAST 71ST STREET,
N
NEW YORK, NY 10021
T
P: (212)772-9416
1
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time
CLINICAL REPORT
Test
Result
Abnormal
Reference
Units
I Previous ResultIDate
Reference Range
Prophylaxis or treatment of venous thrombosis,
2.00-3.00
systemic embolization, and pulmonary embolus
High-risk patients with mechanical heart valves
2.50-3.50
Normal Non-Medicated patients
0.87-1.15 (effective 11-10-15)
NOTE: INR values below 2.00 for patients on warfarin
therapy would be considered sub-therapeutic
for the above conditions.
PTT
26.5
23.6-31.6
sec
I
27.6
10/27/2015
NOTE: The modified activated Partial Thromboplastin Time (APTT) is a screening
procedure for assessment of secondary coagulation, e.g. whether
sufficent fibrinogen and plasma factors are present in amounts for
adequate hemostasis. The extension of the stability to 24 hours for
the APTT is only valid in its use as an initial screening assay of
non-hospitalized patient population. Assessment of factor assays,
unfractionated heparin monitoring, mixing studies, and evaluation
for antiphospholipid-associated APTT abnormalities ("Lupus anticoagulant")
requires strict frozen plasma.
* MISCELLANEOUS *
TSH
1.790
0.178-4.530
uIU/mL
2.060
10/27/2015
THYROXINE(T4)
6.3
4.9-12.9
ug/dL
7.5
10/27/2015
T3 UPTAKE (T3U)
29.3
24.3-39.0
%
29.1
10/27/2015
THYROXINE, FREE (FT4)
0.93
0.80-1.73
ng/dL
1.06
10/27/2015
FREE T4 INDEX
1.8
1.5-3.8
2.2
10/27/2015
T3 (THYRONINE), TOTAL
127
72-180
ng/dL
129
10/27/2015
PSA Total
0.70
<4.00
ng/mL
0.87
10/27/2015
NOTE: The PSA assay should not be the only test used for diagnostic purposes.
Additional evaluation using EIRE, ultrasound, TUR or similar procedures may
be used for this purpose. Predictions of disease recurrence should not be
based solely upon values obtained from serial PSA values obtained on the
patient.
NOTE: Values obtained with different assay methods or kits cannot be
used interchangeably.
NOTE: Results cannot be interpreted as absolute evidence of the presence or
absence of malignant disease.
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics)
PSA, FREE
0.33
Not Estab.
ng/mL
I
0.31
110/27/2015
BioReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, NJ 07407 I (800) 229-5227
James Weisberger M.D.
Page 3 of
5
Laboratory Director
Printed 01/28/2016 15:30
EFTA01107163
BioReference
LABORATORIES
0
T
C
R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720)
P: (212)879-0800
51
EPSTEIN, JEFFREY
P DOB:
Age: 63 y Sex: M
A U/FL:
Bed:
T Rm:
I Patient ID:
E Address:9 EAST 71ST STREET,
N
NEW YORK, NY 10021
T
P: (212)772-9416
PRELIMINARY
1
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time
CLINICAL REPORT
Test
Result
Abnormal
Reference
Units
[ Previous Result' Date
NOTE: Results cannot be interpreted as absolute evidence of the
presence or absence of malignant disease. Values obtained
with different assay methods or kits cannot be used
interchangeably.
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay
(Roche Diagnostics).
% FREE PSA
47
See Below
%
I
36
10/27/2015
FREE PSA RISK ASSESSMENT
The probability of prostate cancer for men with non-suspicious DRE results, by
age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA
values is summarized in the table below:
PROBABILITY OF CANCER*
%free P5A
(50-59 yrs) (60.69 yrs)
(>or.70 yrs)
<or.10
49.2%
57.5%
64.5%
11-18
26.9%
33.9%
40.8%
19-25
18.3%
23.9%
29.7%
>25
9.1%
12.2%
15.8%
*probability of finding prostate cancer by needle biopsy
NOTE: Calculation of percent FREE PSA may not be possible when the value for
TOTAL PSA is in the low normal range. These guidelines are for assays
performed using the Roche E170 immunoassay system.(02/2012;v5)
TESTOSTERONE, TOT.,S.
296.0
193.0-740.0
ng/dL
112.3 LO
10/27/2015
TESTOSTERONE, BIOAVAIL.
183.8
72.0-460.0
ng/dL
74.6
10/27/2015
SEX HORM.BIND.GL06.
18
10-57
nmol/L
14
10/27/2015
FREE TESTOSTERONE
80.18
30.00-150.00
pg/mL
29.82 LO
10/27/2015
LH
6.8
1.7-8.6
mIU/mL
3.7
10/27/2015
FSH
6.8
1.5-12.4
mIU/mL
4.0
10/27/2015
PROLACTIN, SERUM
3.0 LO
4.0-15.2
ng/mL
3.4 LO
10/27/2015
ESTRADIOL
48.93
7.02-49.06
pg/mL
16.00
10/27/2015
FIBRINOGEN
276
176-441
mg/dL
362
10/27/2015
Hemoglobin A1C
6.0 HI
<5.7
%
5.9 HI
10/27/2015
HEMOGLOBIN Alc AND eAG REFERENCE RANGES
A1c(%)
DIABETES CATEGORY*
<5.7
Normal (non-diabetic)
5.7-6.4
Increased risk of diabetes
m>6.5
Consistent with diabetes
A1c(%)
eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)
BioReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, N) 07407 I (800) 229-5227
James Weisberger M.D.
Page 4 of
5
Laboratory Director
Printed 01/28/2016 15:30
EFTA01107164
BioReference
PRELIMINARY
LABORATORIES
D
0
T
C
R
FISCH, HARRY
C1720 - HARRY FISCH, M.D.
944 PARK AVENUE,
NEW YORK, NY 10028
Acct #: (C1720)
P: (212)879-0800
Si
EPSTEIN, JEFFREY
P DOB:
Age: 63 y Sex: M
A U/FL:
Bed:
T Rm:
I Patient ID:
E Address:9 EAST 71ST STREET,
N
NEW YORK, NY 10021
T
P: (212)772-9416 1
Specimen ID: 102449709
Date Of Report: 01/28/2016 02:32
Date Collected: 01/27/2016 12:37
Date Received: 01/27/2016 23:01
North America Eastern Time
CLINICAL REPORT
Test
Result
Abnormal
Reference
Units
I Previous Result! Date
NOTE: Hemolysis,
6
126
7
154
8
183
9
212
10
240
11
269
12
298
*recommended ranges-American Diabetes Association(2010)
rare hemoglobin variants and thalassemia major may affect glycemic results.
DIHYDROTESTOSTERONE
TO FOLLOW
SEE REPORT
153.0
10/27/2015
BioReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, NJ 07407 I (800) 229-5227
James Weisberger M.D.
Page S of
S
LaboratoryDkoMor
Printed 01/28/2016 15:30
EFTA01107165
Technical Artifacts (7)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Phone
(212)772-9416Phone
(212)879-0800Phone
(800) 229-5227Phone
2449709Wire Ref
REFERENCEWire Ref
ReferenceWire Ref
referenceRelated Documents (6)
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.